Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + epirubicin + cyclophosphamide + taxane
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Aipaluoli-tovorilimab + AC-T chemotherapy is a combination treatment regimen consisting of the dual immune checkpoint inhibitor QL1706 (iparomlimab and tuvonralimab) and the standard AC-T chemotherapy regimen (anthracycline/cyclophosphamide followed by a taxane). QL1706, developed by Qilu Pharmaceutical, is a bifunctional biologic composed of two engineered monoclonal antibodies: iparomlimab (an anti-PD-1 IgG4) and tuvonralimab (an anti-CTLA-4 IgG1), combined in a fixed ratio. This combination is being investigated as a postoperative adjuvant therapy for patients with high-risk, lymph node-positive triple-negative breast cancer (TNBC). The regimen aims to leverage the cytotoxic effects of chemotherapy—which can induce immunogenic cell death and release tumor antigens—alongside dual-pathway immune checkpoint blockade to enhance the anti-tumor immune response and improve disease-free survival.
- Brand names
- Avellutolimab
- Other names
- Aipaluoli-tovorilimab + AC-T chemotherapyAipaluoli-tovorilimabQL1706 + AC-TIparomlimab + Tuvonralimab + AC-T
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + epirubicin + cyclophosphamide + taxane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + epirubicin + cyclophosphamide + taxane.